Find stats on top websites
Business and Product Insights
Product Portfolio
Barricaid Annular Closure Device
Barricaid Recurrent Disc Herniation Solution
Intrinsic Therapeutics Key Value Propositions
Barricaid's key value proposition is providing the only FDA-approved, clinically proven implant that significantly reduces reherniation and reoperation rates by closing large annular defects after discectomy. This leads to improved, durable outcomes and enhanced quality of life for patients, offering a 'superior intraoperative choice' for surgeons.
Intrinsic Therapeutics Brand Positioning
Barricaid is positioned as the leading and only FDA-approved bone-anchored implant for preventing reherniation after lumbar discectomy, specifically for patients with large annular defects. It offers a clinically proven solution for superior, long-term patient outcomes.
Top Competitors
Globus Medical
Medtronic
NuVasive (part of Globus Medical)
Customer Sentiments
Customer sentiment is likely positive, especially among surgeons seeking evidence-based solutions for better patient outcomes and patients desiring a durable fix to avoid reoperation and improve quality of life. The emphasis on clinical evidence (Level I RCT) and FDA approval instills confidence.
Actionable Insights
To strengthen brand positioning, Barricaid should highlight its unique, patented technology and superior long-term outcomes to further differentiate itself from traditional approaches and potential competitors.
Products and Features
Barricaid Annular Closure Device - Product Description
The Barricaid Annular Closure Device is an FDA-approved medical device specifically designed to close large defects in the annulus, the outer fibrous ring of the intervertebral disc. Its primary function is to prevent reherniation after discectomy surgery, thereby reducing the need for repeat surgeries and improving long-term patient outcomes. A key feature of Barricaid is its ability to preserve more of the patient's native disc tissue, which is crucial for maintaining spinal biomechanics and function. This device is intended for use in patients undergoing lumbar discectomy for single-level, primary disc herniation.
Pros
- Barricaid is the only FDA-approved annular closure device, providing a unique selling proposition and high regulatory confidence
- It effectively closes large annular defects, significantly reducing the risk of reherniation after discectomy
- The device preserves more of the patient's natural disc, contributing to better long-term spinal health and function.
Cons
- As a specialized surgical implant, the Barricaid device likely involves a higher cost compared to discectomy alone, potentially limiting its widespread adoption
- The procedure requires specific surgical expertise and training for proper implantation, which could restrict its availability to certain surgical centers
- Patient eligibility for Barricaid is limited to specific types of annular defects and disc herniations, meaning it's not universally applicable for all discectomy patients.
Alternatives
- Current alternatives often involve standard discectomy procedures without an additional closure device, relying on natural healing of the annulus
- Other potential alternatives in development or niche use might include suture-based annular repair techniques, though these may not offer the same robust closure for large defects
- Competition could also come from advancements in biological sealants or other implantable devices aiming to prevent disc reherniation, should they gain regulatory approval and market traction.
Company Updates
Latest Events at Intrinsic Therapeutics
Barricaid: Revolutionizing Herniated Disc Surgery
Herniated disc surgery patients benefit from Barricaid, offering a breakthrough solution to lower the risk of reherniation and reoperation in herniated disc ...
View sourceNational Barricade
National Barricade is the Seattle traffic sign rental & traffic barricade construction signs, cones & barriers to Seattle, Bellevue & Tacoma.
View sourceIntrinsic Therapeutics Announces New Category 1 CPT Code for ...
Oct 24, 2024 ... Intrinsic Therapeutics, Inc., the developer of the Barricaid, an FDA approved medical device proven to significantly reduce reherniations ...
View sourceANNULAR CLOSURE - Patient Education Brochure
This brochure will provide you with information about the Barricaid® Annular. Closure Device (ACD), also referred to as “Barricaid,” a new treatment intended.
View sourceTransform Your Ideas into Action in Minutes with WaxWing
Sign up now and unleash the power of AI for your business growth
